Since 1990, helping busy clinicians master the science and art of caring for people with HIV disease.

Latest News

03/04/2013

CROI 2013: Long-acting integrase inhibitor prevents rectal transmission of SHIV in macaques


Pre-exposure Prophylaxis (PrEP) offers a biomedical approach to HIV prevention however non-adherence to the oral drugs may be common and thus limits efficacy. In one of the first sessions of the day, Chastity Andrews from the Aaron Diamond Center in NYC presented preliminary data on a new product from Glaxo Smith Kline, a long acting injectable integrase inhibitor (GSK744LAP), a dolutegravir analog, that may allow once a month dosing due to its plasma half-life of 21-50 days. The efficacy of GSK744LAP was tested in 16 macaques, 8 of whom were given two intramuscular injections of study drug 4 weeks apart, starting 1 week before weekly rectal SHIV exposure for up to 16 weeks. Eight control macaques received no study drug. None of the 8 macaque monkeys receiving the study drug acquired SHIV after intrarectal viral challenges, compared to a 100% infection rate among the 8 macaques that had not received GSK744LAP. This new agent may provide a possible solution to the concerns of non-adherence when using oral PrEP.

Reference:
Andrews C, Gettie A, Russell-Lodrigue K, Moss L, Mohri H, Spreen W, Cheng-Mayer C, Hong Z, Markowitz M, Ho D.et al. Long acting parenteral formulatom of GSK1265744 protects macaque monkeys against repeatd intrarectal challenges with SHIV. Presented March 4, 2013 at the 20th CROI, Atlanta, GA. Oral Abstract 24LB.


Source: Reporting from Atlanta for PRN News: Anita Radix, MD, MPH